Contura’s state-of-the-art manufacturing facility in Denmark has over 20 years of experience producing 2.5% iPAAG* injectables. It is certified according to EU, US and other international standards, using proprietary technology and stringent quality control measures to deliver the highest quality products.
Solely dedicated to the production of 2.5% iPAAG, the facility uses proprietary automated processes to control manufacturing, including the ALPH (Automated Line for Production of Hydrogel), a one-of-a-kind machine designed specifically for Contura.
ALPH’s advanced capabilities and design reflect our commitment to innovation and excellence in hydrogel production.
We have a team of highly qualified scientists and engineers who oversee the production process and ensure our syringes are tightly monitored to meet release specifications.
Our quality management system including product development and manufacturing quality control procedures are approved by the relevant international authorities.
These standards allow us to provide 2.5% iPAAG globally with distribution in the UK, EU, USA, Canada, Australia and beyond.
EC Certificate Annex V 0004 G2S Rev 01
EC Certificate Annex II G1 Rev 02
GMP Authorisation 40290 – DMA
GMP Certificate Korea Exp date 2025 04 26
ISO 13485 Q5 003953 0001 Rev 03
MDR G12 003953 0009 Rev 00
MDR G70 003953 0006 Rev. 00
MDSAP QS6 003953 0005 Rev. 01
DK V 1000971 GMP
DK V 1000971 MIA 40290
MDR G11 003953 0010 Rev. 00
MDR G10 003953 0008 Rev. 00
Contact us
Careers
About us
Team
Privacy notice
© copyright 2025 Contura International Ltd.
*2.5 iPAAG is an injectable polyacrylamide hydrogel known for its unique composition, comprising of 2.5% cross-linked polyacrylamide and 97.5% water.
Arthrosamid is a registered trademark of Contura International A/S.
Contura Vet is a registered trademark of Contura Vet Ltd.